Over the past two months, DOJ has filed
complaints-in-intervention in two FCA cases premised on allegedly
fraudulent diagnosis codes submitted to CMS as a result of
retrospective chart reviews. These cases demonstrate how DOJ has
begun to explore new legal theories that articulate a narrower view
on the legality of retrospective chart reviews designed to add
diagnosis codes.
CMS has repeatedly reiterated, as recently as August 2021, that
adding codes through retrospective chart reviews is permissible in
certain circumstances. See Letter from Chiquita
Brooks-LaSure, Administrator, CMS, to Christi Grimm, Principal
Deputy Inspector General, OIG (Aug. 20, 2021) reprinted in
HHS-OIG, Some Medicare Advantage Companies Leveraged Chart Reviews
and Health Risk Assessments to Disproportionately Drive Payments,
at 21. However, CMS regulations provide only high-level parameters
for how chart reviews should be structured, and CMS has never
issued any clear sub-regulatory